In vivo experiments demonstrated that blocking IL-17 with anti-IL-17A mAb significantly improved liver function and decreased hepatocellular necrosis, pro-inflammatory cytokines, neutrophils and macrophages influx in bile duct ligation-induced liver fibrosis mice (Zhang et al., 2016). Here, IL17A is linked to Hepatic fibrosis.